Evidence-based · Educational only
36+ Peptides indexed
Free research library
Free newsletter — subscribe below
★ = FDA-approved medical indication
Not medical advice — always consult a clinician
Evidence-based · Educational only
36+ Peptides indexed
Free research library
Free newsletter — subscribe below
★ = FDA-approved medical indication
Not medical advice — always consult a clinician
All peptides

Degarelix

Also known as: Firmagon
FDA-Approved

Degarelix is a GnRH antagonist that rapidly suppresses testosterone in the treatment of advanced prostate cancer, without an initial testosterone flare.

Buy Degarelix on American Peptides

Affiliate link — we may earn a commission at no extra cost to you.

Overview

Degarelix is a GnRH antagonist that rapidly suppresses testosterone in the treatment of advanced prostate cancer, without an initial testosterone flare.

FDA Approval Status

Approved by the FDA for at least one medical indication (see approved uses below).

Mechanism of Action

Directly blocks pituitary GnRH receptors, immediately reducing LH, FSH, and testosterone.

Current Research

Head-to-head trials versus leuprolide demonstrate faster testosterone suppression.
Research strength: Strong

Potential Medical Uses

  • Advanced prostate cancer

Potential Benefits

  • No testosterone flare
  • Rapid castrate levels within days

Known Side Effects

  • Hot flashes
  • Injection-site reactions
  • Weight gain
  • Hepatic enzyme elevations

Contraindications

  • Hypersensitivity

Drug Interactions

  • QT-prolonging agents

Administration Methods

  • Subcutaneous injection monthly

Half-life

~53 days (depot)

Reconstitution

Reconstitute per label immediately before injection.

Storage & Handling

Room temperature.

References & Sources

Frequently Asked Questions

Information on this page is educational and general in nature. It is not medical advice. Consult a qualified healthcare professional before making any medical decisions.